March 28, 2022
Access to buprenorphine among Medicaid beneficiaries was not affected during the pandemic.
The COVID-19 pandemic did not disrupt access to buprenorphine but did affect access to opioid use disorder (OUD) treatment services and urine drug testing, according to the results of a new study published in JAMA Health Forum. 1
For more information, visit: https://www.pharmacytimes.com/view/covid-19-pandemic-hurt-oud-services-and-urine-drug-testing-access-study-results-show
Comments